Launch Alert: FDA Approves Tildrakizumab for Active Psoriatic Arthritis
The expanded indication introduces another IL-23 inhibitor option for adults with active PsA, with health care provider administration and dosing considerations relevant to clinical practice.
By Dermsquared Editorial Team | November 18, 2026
Joseph Merola, MD, discusses the recent FDA approval of tildrakizumab for active psoriatic arthritis, highlighting the expanded treatment options for patients with psoriatic disease and the potential access implications of health care provider–administered therapy.
.
The US Food and Drug Administration (FDA) has approved tildrakizumab (Ilumya), a selective interleukin (IL)-23p19 inhibitor, for the treatment of adults with active psoriatic arthritis (PsA). Previously approved for adults with moderate-to-severe plaque psoriasis, tildrakizumab now offers an additional treatment option for patients with PsA, including those with concomitant skin disease.
In this Launch Alert, Joseph Merola, MD, discusses the significance of the expanded indication, with particular attention to treatment access, administration, and the growing role of IL-23 inhibition in psoriatic disease.
Clinical evidence supporting the expanded indication
The approval was supported by 2 randomized, double-blind, placebo-controlled phase 3 trials evaluating tildrakizumab in adults with active PsA. The studies included patients with prior tumor necrosis factor (TNF) inhibitor exposure as well as TNF inhibitor–naive patients.
Across the 2 trials, 806 patients received either tildrakizumab 100 mg or placebo. The primary endpoint was the proportion of patients achieving at least a 20% improvement from baseline in American College of Rheumatology response criteria (ACR20) at Week 24.
In the trial enrolling patients with prior TNF inhibitor exposure, ACR20 responses were achieved by 41% of patients receiving tildrakizumab compared with 25% receiving placebo. In the TNF inhibitor–naive population, corresponding response rates were 35% and 23%, respectively. Both trials met their primary endpoints.
The safety findings were generally consistent with the established safety profile of tildrakizumab.
Dosing and administration considerations
The approved dosing regimen for tildrakizumab in PsA depends on the presence of coexistent moderate-to-severe plaque psoriasis.
For adults with active PsA and coexistent moderate-to-severe plaque psoriasis, the recommended regimen is 100 mg at Weeks 0 and 4, followed by administration every 12 weeks. For other adults with active PsA, the recommended dosage is 100 mg every 12 weeks.
Tildrakizumab is administered by subcutaneous injection by a health care provider, a feature that may influence treatment selection and access considerations for certain patients.
Implications for dermatology practice
Dr Merola emphasizes that the expanded indication builds on dermatologists' familiarity with tildrakizumab in plaque psoriasis, particularly its established use in patients for whom in-office administration may offer access advantages.
He highlights the potential relevance for Medicare beneficiaries and other patients who may encounter challenges accessing self-administered biologic therapies. The availability of a health care provider–administered option approved for both psoriasis and PsA may provide additional flexibility when selecting treatment for patients with overlapping skin and joint disease.
Dr Merola also places the approval within the broader context of IL-23 inhibition in PsA. He notes that emerging evidence involving other agents in the class, including findings related to axial manifestations and radiographic progression, has contributed to growing interest in IL-23 inhibition across different aspects of psoriatic disease. These findings are agent-specific and should not be extrapolated to tildrakizumab.
For dermatologists managing patients with psoriasis who subsequently develop PsA, the expanded indication adds another option to consider when evaluating treatment needs across both conditions. Dr Merola concludes that the approval is particularly noteworthy for the additional access opportunities it may offer patients who could benefit from health care provider–administered therapy.
Key takeaways
Expanded indication: Tildrakizumab is now FDA approved for adults with active PsA, in addition to its established indication for moderate-to-severe plaque psoriasis
Clinical evidence: Two phase 3 trials demonstrated significantly higher ACR20 response rates with tildrakizumab than with placebo at Week 24
Dosing: The approved regimen differs according to whether patients have coexistent moderate-to-severe plaque psoriasis, with every-12-week dosing in both populations
Administration and access: Health care provider administration may offer an additional treatment access pathway for certain patients, including Medicare beneficiaries
Clinical implications: The approval expands the available IL-23 inhibitor options for managing PsA, including in patients with concomitant psoriasis